Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

E-resources

PDF

Peer reviewed Open access

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Herbst, Roy S; Giaccone, Giuseppe; de Marinis, Filippo; Reinmuth, Niels; Vergnenegre, Alain; Barrios, Carlos H; Morise, Masahiro; Felip, Enriqueta; Andric, Zoran; Geater, Sarayut; Özgüroğlu, Mustafa; Zou, Wei; Sandler, Alan; Enquist, Ida; Komatsubara, Kimberly; Deng, Yu; Kuriki, Hiroshi; Wen, Xiaohui; McCleland, Mark; Mocci, Simonetta; Jassem, Jacek; Spigel, David R

New England journal of medicine/The New England journal of medicine, 10/2020, Volume: 383, Issue: 14

Journal Article

Among patients with lung cancer that expressed programmed death ligand 1, the anti–PD-L1 antibody atezolizumab was compared with chemotherapy in a randomized trial. In the subgroup with the highest PD-L1 expression, the median overall survival was 20.2 months with atezolizumab and 13.1 months with chemotherapy.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme